102 related articles for article (PubMed ID: 10945027)
1. [Evidenced-based medicine and future direction of Taxol].
Hatae M; Nakamura T; Ohnishi Y
Gan To Kagaku Ryoho; 2000 Jul; 27(8):1279-87. PubMed ID: 10945027
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel (Taxol): a review of its antitumor activity in clinical studies Minireview.
Hájek R; Vorlicek J; Slavik M
Neoplasma; 1996; 43(3):141-54. PubMed ID: 8841500
[TBL] [Abstract][Full Text] [Related]
3. [Taxol (paclitaxel) as second-line therapy in breast and ovarian cancer].
Borovik R; Steiner M; Atad J; Sneiderman B; Rosenberg T; Palti S
Harefuah; 1998 Apr; 134(8):605-8, 671. PubMed ID: 10911422
[TBL] [Abstract][Full Text] [Related]
4. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel: current developmental approaches of the National Cancer Institute.
Arbuck SG
Semin Oncol; 1995 Dec; 22(6 Suppl 15):55-63. PubMed ID: 8643972
[TBL] [Abstract][Full Text] [Related]
6. Taxol improves outlook for lung, breast, and ovarian cancer.
Oncology (Williston Park); 1992 Aug; 6(8):16. PubMed ID: 1354469
[No Abstract] [Full Text] [Related]
7. Clinical trials referral resource. Clinical trials with taxol.
Cheson BD
Oncology (Williston Park); 1992 Mar; 6(3):67-70. PubMed ID: 1348954
[No Abstract] [Full Text] [Related]
8. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
Ozols RF
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
[TBL] [Abstract][Full Text] [Related]
9. [Taxol--a new cytostatic drug for therapy of ovarian and breast cancer].
Meden H; Rath W; Kuhn W
Geburtshilfe Frauenheilkd; 1994 Apr; 54(4):187-93. PubMed ID: 7912212
[TBL] [Abstract][Full Text] [Related]
10. Weekly paclitaxel in elderly patients (aged > or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study.
Rossi D; Dennetta D; Ugolini M; Alessandroni P; Catalano V; Fedeli SL; Giordani P; Casadei V; Baldelli AM; Graziano F; Catalano G
Clin Lung Cancer; 2008 Sep; 9(5):280-4. PubMed ID: 18824450
[TBL] [Abstract][Full Text] [Related]
11. [Chemotherapy of ovarian and breast cancer with Taxol].
Dtsch Med Wochenschr; 1996 Dec; 121(50 Suppl):1-12. PubMed ID: 9022362
[No Abstract] [Full Text] [Related]
12. Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy.
Clarke K; Lee FT; Brechbiel MW; Smyth FE; Old LJ; Scott AM
Clin Cancer Res; 2000 Sep; 6(9):3621-8. PubMed ID: 10999754
[TBL] [Abstract][Full Text] [Related]
13. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study.
De Placido S; Scambia G; Di Vagno G; Naglieri E; Lombardi AV; Biamonte R; Marinaccio M; Cartenì G; Manzione L; Febbraro A; De Matteis A; Gasparini G; Valerio MR; Danese S; Perrone F; Lauria R; De Laurentiis M; Greggi S; Gallo C; Pignata S
J Clin Oncol; 2004 Jul; 22(13):2635-42. PubMed ID: 15226331
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Morrissey LH; Scullin DC; Houston GA; Prasthofer EF; Gray JR; Burris HA; Greco FA
Cancer; 2002 May; 94(9):2426-33. PubMed ID: 12033195
[TBL] [Abstract][Full Text] [Related]
15. [Taxol].
Kühnle H
Zentralbl Gynakol; 1996; 118(10):580. PubMed ID: 8999717
[No Abstract] [Full Text] [Related]
16. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).
Glorieux P; Ortmanns P; Marien S; Degives R; Degraeve D; Potvin M; Grauwels D; Schallier D
Anticancer Res; 2001; 21(2B):1487-94. PubMed ID: 11396237
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712.
Davies AM; Chansky K; Lau DH; Leigh BR; Gaspar LE; Weiss GR; Wozniak AJ; Crowley JJ; Gandara DR;
J Clin Oncol; 2006 Nov; 24(33):5242-6. PubMed ID: 17114656
[TBL] [Abstract][Full Text] [Related]
18. Front-line paclitaxel and topotecan chemotherapy in advanced or metastatic non-small-cell lung cancer: a phase II trial.
Stathopoulos GP; Katis C; Tsavdaridis D; Dimitroulis J; Karaindros D; Stathopoulos J; Dimou E
Cancer Chemother Pharmacol; 2006 Oct; 58(4):555-60. PubMed ID: 16520987
[TBL] [Abstract][Full Text] [Related]
19. Taxane-based chemoirradiation for organ preservation with locally advanced head and neck cancer: results of a phase II multi-institutional trial.
Cmelak AJ; Murphy BA; Burkey B; Douglas S; Shyr Y; Netterville J
Head Neck; 2007 Apr; 29(4):315-24. PubMed ID: 17252600
[TBL] [Abstract][Full Text] [Related]
20. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials.
Marsland TA; Garfield DH; Khan MM; Look RM; Boehm KA; Asmar L
Lung Cancer; 2005 Jan; 47(1):111-20. PubMed ID: 15603861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]